Published in final edited form as:

J Am Chem Soc. 2010 November 17; 132(45): 15878–15880. doi:10.1021/ja1064312.

Method for the Synthesis of Mono-ADP-ribose Conjugated Peptides

Peter M. Moyle and Tom W. Muir

Laboratory of Synthetic Protein Chemistry, the Rockefeller University, New York, New York 10065

Tom W. Muir: tmuir@rockefeller.edu

Abstract

ADP-ribosylation is an important post-translational modification involved in processes including cellular replication, DNA repair, and cell death. Despite these roles, the functions of ADP-ribosylation, in particular mono-ADP-ribosylation, remain poorly understood. The development of a technique to generate large amounts of site-specific, ADP-ribosylated peptides would provide a useful tool for deconvoluting the biochemical roles of ADP-ribosylation. Here we demonstrate that synthetic histone H2B tail peptides, incorporating aminooxy or *N*-methyl aminooxy functionalized amino acids, can be site-specifically conjugated to ADP-ribose. These peptides are recognized as substrates by the ADP-ribosylation biochemical machinery (PARP1), can interact with the ADP-ribose binding proteins *macroH2A1.1* and PARP9, and demonstrate superior enzymatic and chemical stability when compared to ester-linked ADP-ribose. In addition, the incorporation of benzophenone photocrosslinkers into these peptides is demonstrated to provide a means to probe for, and enrich ADP-ribose binding proteins.

ADP-ribosylation involves the transfer of ADP-ribose (ADPR) from β -NAD⁺ onto protein substrates.¹ A family of enzymes termed poly(ADP-ribose) polymerases (PARPs), which generate protein-linked ADPR monomers (mono-ADP-ribosylation) or polymers (poly-ADP-ribosylation), catalyze this reaction. ADP-ribosylation occurs on several residues including glutamic acid where the attachment is through an ester linkage.¹ The functional roles of ADP-ribosylation, in particular mono-ADP-ribosylation, are poorly understood. The study of ADP-ribosylation has proven difficult for many reasons. For example, the ester-linked ADPR generated by PARPs is unstable at basic pH ($t_{1/2} < 1$ h pH 7.5^{1b}), and endogenous enzymes rapidly cleave poly-ADP-ribose polymers (e.g. poly(ADP-ribose) glycohydrolase; $t_{1/2}$ 0.6–6 min^{1b}). There is also a lack of commercial antibodies specific for mono-ADP-ribose, mono-ADP-ribose protein-linkages, or poly-ADP-ribose branching.¹ The ability to site-specifically attach ADPR to peptides/proteins would provide a useful tool for studying the biochemical effects of this modification. Such a technique, using a protected mono-ADP-ribosylated asparagine building block for peptide synthesis has recently been described.² In this report, we demonstrate the use of aminooxy-functionalized amino acids to enable site-specific attachment of ADPR onto peptides. Using this technology, we show that an ADP-ribosylated version of the histone H2B tail can interact with the ADPR binding protein, *macroH2A1.1* (mH2A1.1), and demonstrate that incorporation of photocrosslinkers into these peptides improves their ability to detect ADPR binding proteins.

Correspondence to: Tom W. Muir, tmuir@rockefeller.edu.

Supporting Information **Available:** Experimental procedures, characterization data, complete ref 9b, and supporting figures. This material is available free of charge via the Internet at <http://pubs.acs.org>.

We set out to develop a general strategy for the synthesis of mono-ADPR peptide-conjugates. In principle, a chemoselective ligation approach would allow precise control over the ADPR conjugation site using readily accessible building blocks. This would enable large amounts of ADPR conjugated peptides to be synthesized for biochemical studies. Further, the chemical approach would allow the incorporation of linkers featuring improved chemical and enzymatic stability, when compared to enzymatic ADP-ribosylation. Uses for such a method would include the investigation of protein interactions, the potential to generate site-specific poly-ADP-ribosylated peptides through a templated initiator ADPR residue,³ and the generation of ADPR conjugated proteins using expressed protein ligation.⁴

Under physiological conditions, ADPR (Scheme 1A) reacts with lysine and arginine side-chains to form imine-linked species, which degrade to give a mixture of products.⁵ While this process does not provide a route to stable, site-specific ADPR-peptide conjugates, it suggested to us that oxime ligation might prove suitable for this purpose. Oxime ligation is performed at ~ pH 4.5, a pH at which peptide lysine and arginine residues are protonated and unreactive. In addition, oxime ligation is compatible with all natural amino acid functional groups, and the oxime linkage is significantly more stable to hydrolysis compared to imines or the native ADPR ester linkage.⁶ Ligation of reducing-carbohydrates through an oxime, using an aminooxy group, generates mainly ring-opened carbohydrates, with a small amount of the ring-closed form (Scheme 1B).⁷ Conversion of the aminooxy group to a secondary alkoxyamine, through *N*-methylation, results in the attached carbohydrates adopting a ring-closed form exclusively (Scheme 1C).^{7b} Based on these observations, we decided to investigate if aminooxy and *N*-methyl aminooxy functionalized peptides could undergo site-specific ligation reactions with ADPR.

Histone H2B was selected as a model for ADPR conjugation as it has been reported to be mono-ADP-ribosylated on glutamate residue 2 in rat liver.⁸ In preliminary studies, we found this modification can also occur on glutamate-2 of human H2B *in vitro* using recombinant PARP10 (Figure S1), which has been shown to mono-ADP-ribosylate histones.⁹ Moreover, we demonstrated that human H2B is a major acceptor of ADP-ribosylation in HeLa cell nuclei (Figure S2).

A series of peptides corresponding to the N-terminus of human histone H2B were synthesized on solid-phase (**1-8**; Table 1). Several of these peptides contained suitably protected versions of aminooxy-containing building block **10**¹⁰ or *N*-methyl aminooxy-containing amino acid **11**¹¹ substituted for glutamic acid residue 2. Peptides incorporating **10** or **11** were ligated to ADPR in 0.5 M sodium acetate (~ pH 4.5) to generate mimetics of the mono-ADP-ribosylated H2B amino-terminal tail. Ligation reactions to peptides incorporating **10** were rapid, completing in less than 1 h at 30 °C using 1.2-10 eq. of ADPR (Figure 1A). Ligation to **3**, incorporating **11**, was slow, required a larger excess of ADPR (≥ 10 eq), and never reached completion (< 40 % by 3 days; Figure 1B). The amount of **3a** obtained after purification was not sufficient for in depth biochemical studies. Attempts to improve the reaction rate and yield of **3a** through the addition of aniline¹² (0.1-100 mM) to ligations were unsuccessful, leading to the formation of multiple ADP-ribose associated products (Figure S3A). Aniline, however, accelerated α -glucose ligation to **3** by 7-fold (Figure S3B), demonstrating that this molecule can accelerate the ligation of carbohydrates to *N*-methyl aminooxy groups. The site-specific ligation to peptides incorporating **10** was confirmed by analyzing tryptic digests of **2a** (Figure S4). Ligation through the ADPR distal ribose was established by treating **9a** with snake venom phosphodiesterase and calf intestinal alkaline phosphatase, which left a species identical in mass to the peptide conjugated to the ADPR distal ribose (Figure S5). The *E* and *Z* oxime-linked species were observed by NMR in a 2:1 ratio (Figure S6). Peptide **6a** was assessed for stability to a variety of conditions (pH, nucleophiles, lysates, enzymes), with the oxime ADPR linkage

found to be significantly more stable to conditions known to rapidly cleave the native ADPR-protein ester linkage (Figure S7).^{8a,9a}

We were keen to assess whether an ADPR-peptide conjugate could be used to nucleate the site-specific generation of poly-ADP-ribosylated peptides using recombinant PARPs and β -NAD⁺. Indeed, we found that PARP1 can transfer ADP-ribose on to ADPR-containing peptide **6a**, but not on to control peptides **4** or **5** which lack the ADPR template (Figure S8). Thus, site-specific poly-ADP-ribose peptide conjugates can be accessed using this chemoenzymatic strategy.

Next we sought to demonstrate that the peptide ADPR conjugates could interact with a known ADPR binding protein. Several so-called *macro* domains have been shown to bind ADPR,¹³ and it is postulated that ADP-ribosylated proteins may also interact with these domains.^{13b,14} Indeed, a recent report suggests that the *macro* domain containing histone, mH2A1.1, can bind poly-ADP-ribosylated PARP1.^{14c} Since histones H2B and mH2A1.1 exist in the same nuclear environment (i.e. within nucleosome core particles of chromatin), we asked if mH2A1.1 could bind the synthetic ADPR conjugated peptides using a peptide pull-down assay. A splice-variant, mH2A1.2, which does not bind ADPR,^{13c} was used as a negative control in this experiment. Peptides **1**, **2a** and **9a** were assessed for their ability to interact with mH2A1.1 and mH2A1.2 (Figure 2). ADPR-peptide conjugates **2a** and **9a** were able to pull-down mH2A1.1, but not mH2A1.2. Control peptide **1** did not interact with mH2A1.1, suggesting that the ADPR moiety is important for the interaction. Consistent with this, peptide **2a** did not pull-down with a point-mutant of mH2A1.1 (G224E) (Figure S9) which abolishes ADPR binding.^{13c} Interestingly, peptide **2a** pulls down more mH2A1.1 than peptide **9a**, suggesting that the H2B peptide sequence in **2a** also contributes to the interaction. Additional studies will be needed to confirm this. The key result here is that the ADPR-peptide conjugates afforded by our strategy are able to interact with the *macro* domain. To our knowledge, this is the first demonstration that an ADPR binding domain can engage the modification when it is covalently linked to a peptide carrier.

We imagined that our ADPR-peptide conjugates could be useful in the identification of novel ADPR-binding proteins from crude cellular lysates. The affinity of free ADPR for mH2A1.1 is modest, in the μ M range.^{13c} Thus, we were concerned that affinity-capture methods might not be fruitful. Indeed, peptide **2a** was unable to pull-down low concentrations of mH2A1.1 doped into HeLa S3 nuclear lysates (Figure 3, lane 6). One approach to overcome this problem would be to incorporate a photocrosslinker into the conjugate, thereby covalently linking the probe to the target.¹⁵ With this in mind, we synthesized ADPR-peptide conjugate **8a** featuring benzophenone crosslinker **12** appended to the N-terminus of the H2B sequence (Table 1). We also synthesized peptide **7**, which contains the crosslinker but lacks the ADPR moiety. Incubation of peptide **8a**, but not **7**, with HeLa S3 nuclear lysates doped with mH2A1.1 followed by UV irradiation, resulted in the generation of a robust crosslink to the *macro* domain (Figure 3). This effect was observed at two *macro* domain concentrations, differing by 5-fold. At the higher concentration, peptide **8a** was able to pull down both crosslinked mH2A1.1 and non-crosslinked mH2A1.1 (upper and lower bands, respectively, in the α -His blot of the precipitated material, Figure 3). Since the mH2A1.1 *macro* domain can form dimers,¹⁶ this data suggests that the crosslinked species may co-precipitate interacting proteins in their native state. In addition, PARP9, a known ADP-ribose binding protein,^{13b} could be enriched from Farage nuclear lysates after crosslinking with peptide **8a**, but not with **7** (Figure S10). Based on these observations, incorporation of photocrosslinkers and ADPR into peptides could be useful for enriching, or probing for ADPR binding proteins.

Research into ADP-ribosylation has proven difficult due to the paucity of tools available for studying this modification. Several β -NAD⁺-based chemical probes have been described.¹⁷ These analogues, if recognized by ADP-ribosylating enzymes, offer the potential to detect and enrich ADP-ribosylated proteins. The sites of modification, however, depend on the enzyme used, and unstable ADPR-protein linkages may be generated. In contrast, the methodology described in this study enables multi-milligram amounts of highly pure, stable and site-specific ADPR peptide-conjugates to be generated. The ADPR peptide-conjugates can bind to the mH2A1.1 and PARP9 *macro* domains, the first demonstration that a *macro* domain can engage ADPR when linked to a peptide. Moreover, the ADPR peptide-conjugates could be poly-ADP-ribosylated by PARP1, and incorporation of photocrosslinkers allowed the capture of ADPR-binding proteins from lysates. Consequently, this technique may be useful for identifying and enriching ADPR binding proteins, and may enable the generation of site-specifically poly-ADP-ribosylated peptides and proteins for biochemical assays.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was funded by the US National Institutes of Health (GM086868 & RC2CA148354). P.M.M. was supported by the American Australian Association and the Australian National Health and Medical Research Council. We thank C.D. Allis, H. Kleine, X. Li, S. Lockless, B. Lüscher, R. McGinty, M. Pratt, A. Ruthenburg, R. Subramanian, J. Weinger and members of the Muir laboratory.

References

1. (a) Hottiger MO, Hassa PO, Luscher B, Schuler H, Koch-Nolte F. Trends Biochem Sci. 2010; 35:208–219. [PubMed: 20106667] (b) Hassa PO, Haenni SS, Elser M, Hottiger MO. Microbiol Mol Biol Rev. 2006; 70:789–829. [PubMed: 16959969]
2. van der Heden van Noort GJ, van der Horst MG, Overkleef HS, van der Marel GA, Filippov DV. J Am Chem Soc. 2010; 132:5236–5240. [PubMed: 20232863]
3. Ueda K, Kawaichi M, Okayama H, Hayaishi O. J Biol Chem. 1979; 254:679–687. [PubMed: 762090]
4. Muir TW, Sondhi D, Cole PA. Proc Natl Acad Sci U S A. 1998; 95:6705–6710. [PubMed: 9618476]
5. Cervantes-Laurean D, Jacobson EL, Jacobson MK. J Biol Chem. 1996; 271:10461–10469. [PubMed: 8631841]
6. Kalia J, Raines RT. Angew Chem Int Ed Engl. 2008; 47:7523–7526. [PubMed: 18712739]
7. (a) Cervigni SE, Dumy P, Mutter M. Angew Chem Int Ed Engl. 1996; 35:1230–1232. (b) Peri F, Dumy P, Mutter M. Tetrahedron. 1998; 54:12269–12278.
8. (a) Burzio LO, Riquelme PT, Koide SS. J Biol Chem. 1979; 254:3029–3037. [PubMed: 218926] (b) Ogata N, Ueda K, Hayaishi O. J Biol Chem. 1980; 255:7610–7615. [PubMed: 7400135]
9. (a) Kleine H, Poreba E, Lesniewicz K, Hassa PO, Hottiger MO, Litchfield DW, Shilton BH, Luscher B. Mol Cell. 2008; 32:57–69. [PubMed: 18851833] (b) Yu M, et al. Oncogene. 2005; 24:1982–1993. [PubMed: 15674325]
10. Wahl F, Mutter M. Tetrahedron Lett. 1996; 37:6861–6864.
11. Carrasco MR, Brown RT. J Org Chem. 2003; 68:8853–8858. [PubMed: 14604354]
12. Dirksen A, Hackeng TM, Dawson PE. Angew Chem Int Ed Engl. 2006; 45:7581–7584. [PubMed: 17051631]
13. (a) Egloff MP, Malet H, Putics A, Heinonen M, Dutartre H, Frangeul A, Gruez A, Campanacci V, Cambillau C, Ziebuhr J, Ahola T, Canard B. J Virol. 2006; 80:8493–8502. [PubMed: 16912299] (b) Karras GI, Kustatscher G, Buhecha HR, Allen MD, Pugieux C, Sait F, Bycroft M, Ladurner

- AG. EMBO J. 2005; 24:1911–1920. [PubMed: 15902274] (c) Kustatscher G, Hothorn M, Pugieux C, Scheffzek K, Ladurner AG. Nat Struct Mol Biol. 2005; 12:624–625. [PubMed: 15965484]
14. (a) Dani N, Stilla A, Marchegiani A, Tamburro A, Till S, Ladurner AG, Corda D, Di Girolamo M. Proc Natl Acad Sci U S A. 2009; 106:4243–4248. [PubMed: 19246377] (b) Till S, Ladurner AG. Front Biosci. 2009; 14:3246–3258. [PubMed: 19273270] (c) Timinszky G, Till S, Hassa PO, Hothorn M, Kustatscher G, Nijmeijer B, Colombelli J, Altmeyer M, Stelzer EHK, Scheffzek K, Hottiger MO, Ladurner AG. Nat Struct Mol Biol. 2009; 16:923–U941. [PubMed: 19680243]
15. Kauer JC, Erickson-Viitanen S, Wolfe HR, Degrado WF. J Biol Chem. 1986; 261:10695–10700. [PubMed: 3733726]
16. Vijay-Kumar S, Chandra N, Dharia C, Pehrson JR. Proteins. 1995; 22:290–292. [PubMed: 7479703]
17. (a) Du JT, Jiang H, Lin HN. Biochemistry. 2009; 48:2878–2890. [PubMed: 19220062] (b) Kim HT, Haley BE. J Biol Chem. 1990; 265:3636–3641. [PubMed: 2303469] (c) Zhang J, Snyder SH. Biochemistry. 1993; 32:2228–2233. [PubMed: 8443164]

Figure 1.

Ligation of ADPR to (a) **2** or (b) **3**, with representative RP-HPLC and ESI-MS data for starting peptides and their respective products (**2a** and **3a**) at specified times. The products absorb at 259 nm due to the presence of the ADPR associated adenine.

Figure 2.

Binding of synthetic biotinylated peptides to mH2A1.1. Indicated peptides were incubated with either mH2A1.1 or, as a control, mH2A1.2. Peptides were then immobilized using streptavidin-beads and captured complexes analyzed by SDS-PAGE followed by western blotting against the His₆-tag on the protein. Equal loading of peptides was shown by RP-HPLC.

Figure 3.

Photocrosslinking studies. Indicated peptides were incubated with HeLa cell nuclear lysates doped with mH2A1.1 at two concentrations. Mixtures were then irradiated with UV light (or not in the case of peptide **2a**) and then immobilized using streptavidin-beads. Captured complexes were analyzed by SDS-PAGE followed by western blotting against mH2A1.1 (α -His₆) or the peptide (streptavidin-HRP).

Scheme 1.

The structure of (A) ADPR and its ligation to (B) aminooxy and (C) *N*-methyl aminooxy functionalized peptides.

Table 1

Synthetic peptide library.

$AA^1-AA^2-AA^3-\boxed{\text{Peptide}}-Lys(R^1)-AA^4-NH_2$					
Compound	AA ¹	AA ²	AA ³	Peptide ^a	R ¹ AA ⁴
1	-	Pro	Glu	H2B(3-19)	Biotin -
2	-	Pro	10	H2B(3-19)	Biotin -
2a	-	Pro	10a	H2B(3-19)	Biotin -
3	-	Pro	11	H2B(3-19)	Biotin -
3a	-	Pro	11a	H2B(3-19)	Biotin -
4	-	Pro	Glu	H2B(3-19)	- -
5	-	Pro	Ala	H2B(3-19)	- -
6	-	Pro	10	H2B(3-19)	- -
6a	-	Pro	10a	H2B(3-19)	- -
7	12	Pro	Glu	H2B(3-19)	Biotin -
8	12	Pro	10	H2B(3-19)	Biotin -
8a	12	Pro	10a	H2B(3-19)	Biotin -
9	10	Gly	Gly	-	Biotin Gly
9a	10a	Gly	Gly	-	Biotin Gly

10: R² = H
10a: R² = ADPR

11: R³ = H
11a: R³ = ADPR

12

^aH2B(3-19) Sequence: PAK SAPAP KKGSK KAVT